Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 6:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 89 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: UCB Biopharma SRL Clear all
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis

NCT07219420
View directory record Official record
Conditions
Palmoplantar Pustulosis
Interventions
Bimekizumab, Placebo
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
8
States / cities
Birmingham, Alabama • Fremont, California • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 7, 2026, 6:55 AM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy

NCT04666610
View directory record Official record
Conditions
Childhood Absence Epilepsy, Juvenile Absence Epilepsy
Interventions
Brivaracetam, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
2 Years to 25 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
10
States / cities
Birmingham, Alabama • Orange, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 7, 2026, 6:55 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Adult Patients With Chronic Plaque Psoriasis

NCT03230292
View directory record Official record
Conditions
Chronic Plaque Psoriasis
Interventions
Bimekizumab
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years to 70 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
High Point, North Carolina • Bexley, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 22, 2022 · Synced Oct 7, 2026, 6:55 AM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis

NCT06506916
View directory record Official record
Conditions
Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis
Interventions
bimekizumab
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
6
States / cities
Birmingham, Alabama • Fountain Valley, California • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 7, 2026, 6:55 AM EDT
Recruiting No phase listed Observational

SLC6A1-NDD Prospective Longitudinal Natural History Study

NCT07531511
View directory record Official record
Conditions
SLC6A1 Neurodevelopmental Disorder (NDD), Developmental and Epileptic Encephalopathies (DEE)
Interventions
Not listed
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
Up to 17 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 7, 2026, 6:55 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis

NCT03896581
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Bimekizumab, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
33
States / cities
Phoenix, Arizona • San Diego, California • Tustin, California + 30 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 7, 2026, 6:55 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Long Term Safety and Efficacy of Bimekizumab in Subjects With Ankylosing Spondylitis

NCT03355573
View directory record Official record
Conditions
Ankylosing Spondylitis
Interventions
Bimekizumab
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
3
States / cities
Sarasota, Florida • Duncansville, Pennsylvania • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Oct 7, 2026, 6:55 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Test the Long-term Safety and Tolerability of Brivaracetam in Study Participants With Childhood Absence Epilepsy or Juvenile Absence Epilepsy

NCT06315322
View directory record Official record
Conditions
Childhood Absence Epilepsy, Juvenile Absence Epilepsy
Interventions
Brivaracetam Film-coated tablet, Brivaracetam oral solution
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
2 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
3
States / cities
Birmingham, Alabama • New Brunswick, New Jersey • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 7, 2026, 6:55 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)

NCT04596995
View directory record Official record
Conditions
Primary Immune Thrombocytopenia
Interventions
Rozanolixizumab
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 5, 2024 · Synced Oct 7, 2026, 6:55 AM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis

NCT04436640
View directory record Official record
Conditions
Axial Spondyloarthritis, Ankylosing Spondylitis, r-axSpa, Nr-axSpa
Interventions
Bimekizumab
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
508 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
10
States / cities
Glendale, Arizona • Phoenix, Arizona • Upland, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 7, 2026, 6:55 AM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Pharmacokinetics, Safety, and Effectiveness of Certolizumab Pegol in Children With Moderate to Severe Chronic Plaque Psoriasis

NCT04123795
View directory record Official record
Conditions
Moderate Chronic Plaque Psoriasis, Severe Chronic Plaque Psoriasis, Mixed Guttate/Plaque Psoriasis
Interventions
Certolizumab pegol, Placebo
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
6 Years to 17 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
15
States / cities
Phoenix, Arizona • Fountain Valley, California • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 7, 2026, 6:55 AM EDT
Completed Phase 2 Interventional Results available

A Study to Test the Efficacy, Safety and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa.

NCT03248531
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Bimekizumab, Adalimumab, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years to 70 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
11
States / cities
Los Angeles, California • Coral Gables, Florida • Orange, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2022 · Synced Oct 7, 2026, 6:55 AM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis

NCT06624228
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Bimekizumab, Risankizumab, Placebo
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
553 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
34
States / cities
Gilbert, Arizona • Glendale, Arizona • Phoenix, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 7, 2026, 6:55 AM EDT
Completed Phase 3 Interventional Results available

A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis

NCT04124965
View directory record Official record
Conditions
Generalized Myasthenia Gravis
Interventions
Rozanolixizumab
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
10
States / cities
Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 7, 2026, 6:55 AM EDT
Completed Phase 1 Interventional

A Study to Assess the Pharmacokinetics (PK) and Safety of Staccato Alprazolam in Adolescent Study Participants With Epilepsy

NCT04857307
View directory record Official record
Conditions
Epilepsy
Interventions
Alprazolam
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
12 Years to 17 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
8
States / cities
Little Rock, Arkansas • Orlando, Florida • Honolulu, Hawaii + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2022 · Synced Oct 7, 2026, 6:55 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Zilucoplan Concentration in Breast Milk of Healthy Lactating Women

NCT06961747
View directory record Official record
Conditions
Healthy Participants
Interventions
Zilucoplan
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
2
States / cities
San Antonio, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 7, 2026, 6:55 AM EDT
Recruiting Phase 2 Interventional

A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis

NCT07725939
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease With Chronic Bronchitis
Interventions
Galvokimig, Placebo
Biological
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
40 Years to 80 Years
Enrollment
402 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
3
States / cities
Columbus, Ohio • DuBois, Pennsylvania • Boerne, Texas
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 7, 2026, 6:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Time to Onset of Action of Staccato Alprazolam Versus Midazolam and Diazepam in Healthy Participants

NCT07020988
View directory record Official record
Conditions
Healthy Participants
Interventions
Staccato Alprazolam, Midazolam, Diazepam
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
20 Years to 55 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 7, 2026, 6:55 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Single-ascending Dose (Part A) and Repeat-dose (Part B) Study to Investigate the Safety, Pharmacokinetics and Efficacy (Part B Only) of UCB1381 in Healthy Study Participants (Part A) and in Study Participants With Moderate to Severe Atopic Dermatitis (Part B)

NCT05277571
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
UCB1381, Placebo
Biological · Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years to 65 Years
Enrollment
109 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
16
States / cities
Beverly Hills, California • Glendale, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 7, 2026, 6:55 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Active Psoriatic Arthritis

NCT04109976
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Bimekizumab
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
20
States / cities
Boise, Idaho • Lexington, Kentucky • Baton Rouge, Louisiana + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2023 · Synced Oct 7, 2026, 6:55 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa

NCT04242498
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Bimekizumab, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
509 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
24
States / cities
Fountain Valley, California • Thousand Oaks, California • Miami, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 7, 2026, 6:55 AM EDT
Recruiting Phase 2Phase 3 Interventional

A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis

NCT06055959
View directory record Official record
Conditions
Generalized Myasthenia Gravis
Interventions
Zilucoplan
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
12 Years to 17 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Chicago, Illinois • Denton, Texas
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 7, 2026, 6:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Relative Bioavailability Study of Staccato Alprazolam Versus Oral Alprazolam in Healthy Study Participants

NCT05626439
View directory record Official record
Conditions
Healthy Participants
Interventions
Staccato alprazolam, Oral alprazolam
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years to 55 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 18, 2024 · Synced Oct 7, 2026, 6:55 AM EDT
Terminated Phase 2 Interventional Results available

Study to Test the Safety and Efficacy of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy

NCT03370120
View directory record Official record
Conditions
Drug-Resistant Epilepsy, Focal-Onset Seizures
Interventions
Padsevonil
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
406 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
25
States / cities
Chandler, Arizona • La Jolla, California • San Francisco, California + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2021 · Synced Oct 7, 2026, 6:55 AM EDT